ARIKAYCE Shows Promise Earlier in MAC Lung Disease, Phase 3b ENCORE Data Suggest
New data from the Phase 3b ENCORE study indicate that ARIKAYCE (amikacin liposome inhalation suspension) may offer meaningful clinical benefit earlier in the treatment course for patients with Mycobacterium avium complex (MAC) lung disease, a serious and …